These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 9030239

  • 1. Potential role of platelets and coagulation factors in the metastasis of prostatic cancer.
    Bhatti RA, Gadarowski J, Ray P.
    Invasion Metastasis; 1996; 16(2):49-55. PubMed ID: 9030239
    [Abstract] [Full Text] [Related]

  • 2. Metastatic behavior of prostatic tumor as influenced by the hematopoietic and hematogenous factors.
    Bhatti RA, Gadarowski JJ, Ray PS.
    Tumour Biol; 1997; 18(1):1-5. PubMed ID: 8989919
    [Abstract] [Full Text] [Related]

  • 3. Platelet aggregating material (PAM) of two virally-transformed tumors: SV3T3 mouse fibroblast and PW20 rat renal sarcoma. Role of cell surface sialylation.
    Karpatkin S, Pearlstein E, Salk PL, Yogeeswaran G.
    Prog Clin Biol Res; 1982; 89():445-77. PubMed ID: 7111309
    [Abstract] [Full Text] [Related]

  • 4. Platelet aggregation inhibitors and metastatic spread of neoplastic cells.
    Ambrus JL, Ambrus CM, Gastpar H.
    Prog Clin Biol Res; 1982; 89():83-95. PubMed ID: 7111311
    [No Abstract] [Full Text] [Related]

  • 5. [Cancer blood-borne metastasis and platelets].
    Tanaka K, Fukumoto S.
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2453-9. PubMed ID: 6391385
    [Abstract] [Full Text] [Related]

  • 6. [Coagulo-fibrinolytic system and platelets in cancer--clinical and experimental study on the influence of coagulo-fibrinolytic system and platelets on tumor growth and metastasis].
    Ojiro M.
    Igaku Kenkyu; 1983 Mar; 53(2):63-99. PubMed ID: 6375232
    [No Abstract] [Full Text] [Related]

  • 7. Platelet cancer cell interaction in metastasis formation. Platelet aggregation inhibitors: a possible approach to metastasis prevention.
    Gastpar H, Ambrus JL, Ambrus CM.
    Prog Clin Biol Res; 1982 Mar; 89():63-82. PubMed ID: 7111310
    [Abstract] [Full Text] [Related]

  • 8. [Disordered function of the vascular-thrombocyte link in the hemostatic system during tumor growth].
    Liubina LV, Tlepshukov IK.
    Biull Eksp Biol Med; 1989 Dec; 108(12):716-8. PubMed ID: 2634448
    [Abstract] [Full Text] [Related]

  • 9. [Inhibition of metastasis by anti-platelet agents-prostaglandins].
    Niitsu Y, Urushizaki I.
    Gan To Kagaku Ryoho; 1985 Jun; 12(6):1228-34. PubMed ID: 3890759
    [Abstract] [Full Text] [Related]

  • 10. Role of prostacyclin as a natural deterrent to hematogenous tumor metastasis.
    Honn KV, Menter DG, Onoda JM, Taylor JD, Sloane BF.
    Symp Fundam Cancer Res; 1983 Jun; 36():361-88. PubMed ID: 6382514
    [No Abstract] [Full Text] [Related]

  • 11. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T, Nutahara K, Higashihara E.
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [Abstract] [Full Text] [Related]

  • 12. Viable circulating metastatic cells produced in orthotopic but not ectopic prostate cancer models.
    Glinskii AB, Smith BA, Jiang P, Li XM, Yang M, Hoffman RM, Glinsky GV.
    Cancer Res; 2003 Jul 15; 63(14):4239-43. PubMed ID: 12874032
    [Abstract] [Full Text] [Related]

  • 13. Thrombospondin, a potentiator of tumor cell metastasis.
    Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA, Gasic GJ.
    Cancer Res; 1987 Aug 01; 47(15):4130-3. PubMed ID: 3607754
    [Abstract] [Full Text] [Related]

  • 14. [Role of blood platelets and prostaglandins in blood-borne metastases].
    Tanaka K, Fukumoto S.
    Gan To Kagaku Ryoho; 1983 Sep 01; 10(9):1944-7. PubMed ID: 6614932
    [Abstract] [Full Text] [Related]

  • 15. Nb rat prostate adenocarcinoma model: metastasis.
    Drago JR, Curley RM, Sipio JC.
    Anticancer Res; 1985 Sep 01; 5(2):193-6. PubMed ID: 2581494
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of platelet function: does it offer a chance of better cancer progression control?
    Sierko E, Wojtukiewicz MZ.
    Semin Thromb Hemost; 2007 Oct 01; 33(7):712-21. PubMed ID: 18000800
    [Abstract] [Full Text] [Related]

  • 17. Mechanistic explanation for platelet contribution to cancer metastasis.
    Stegner D, Dütting S, Nieswandt B.
    Thromb Res; 2014 May 01; 133 Suppl 2():S149-57. PubMed ID: 24862136
    [Abstract] [Full Text] [Related]

  • 18. Antimetastatic agents. II. Summary of the interactions of tumor cells with blood coagulation factors, platelets, fibrinolytic factors, and inflammatory cells and their soluble mediators: potential for therapeutic interventions.
    Rickles FR, Hancock WW.
    Semin Thromb Hemost; 1988 Jan 01; 14(1):126-32. PubMed ID: 3353730
    [Abstract] [Full Text] [Related]

  • 19. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
    Nemeth JA, Harb JF, Barroso U, He Z, Grignon DJ, Cher ML.
    Cancer Res; 1999 Apr 15; 59(8):1987-93. PubMed ID: 10213511
    [Abstract] [Full Text] [Related]

  • 20. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer.
    Xia W, Unger P, Miller L, Nelson J, Gelman IH.
    Cancer Res; 2001 Jul 15; 61(14):5644-51. PubMed ID: 11454719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.